Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

NEXT STORY
Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
PREV STORY
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medigus Broadens Availability of MUSE™ Through Distribution Agreement with MELEKIRMAK in Turkey, Azerbaijan and Georgia

OMER, Israel, May 14, 2018 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a medical ...

author_avatar
NASDAQ Market News

Alabama State University Adopts Full Draganfly COVID-19 Safety Protocol Part of the National Safely Opening Schools Program

author_avatar
NASDAQ Market News

Sensus Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results

author_avatar
NASDAQ Market News